Risk stratification in multiple myeloma: Are we there yet?

The second revision of international staging system (R2‐ISS) shows promise in patients with multiple myeloma treated with a regimen of novel agent‐based induction therapy, autologous stem cell transplant and maintenance therapy, but challenges persist. This study by Alzahrani et al. underscores the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2024-05, Vol.204 (5), p.1585-1587
Hauptverfasser:	Mohan, Meera, Schinke, Carolina
Format:	Artikel
Sprache:	eng
Schlagworte:	Autografts Hematopoietic stem cells Induction therapy Multiple myeloma R2‐ISS staging system Risk assessment risk stratification Stem cell transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The second revision of international staging system (R2‐ISS) shows promise in patients with multiple myeloma treated with a regimen of novel agent‐based induction therapy, autologous stem cell transplant and maintenance therapy, but challenges persist. This study by Alzahrani et al. underscores the importance of refining risk assessment tools for tailored treatment strategies. Commentary on: Alzahrani et al. Impact of revised international staging system 2 (R2‐ISS) risk stratification on outcomes of patients with multiple myeloma receiving autologous hematopoietic stem cell transplantation. Br J Haematol 2024;204:1944‐1952.
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.19416